326030:KRXSK Biopharmaceuticals Co., Ltd. Analysis
Data as of 2026-09-12 - not real-time
₩79,400.00
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
At KRW 79,400.00, SK Biopharmaceuticals Co., Ltd. shows no decisive moving-average alignment, leaving the trend neutral. Over a rolling month the price has gained 2.3%. With RSI at 38.3 the momentum picture is approaching oversold, alongside a bearish MACD signal. Recent trading has carved out support near KRW 77,200.00 and resistance around KRW 94,800.00.
The shares look undervalued, trading on 15.2 times earnings below a sector average of 29.5. The average analyst target implies 64.1% above today's level. Revenue is growing at 40.3% on a 46.6% profit margin.
Risk scores 6 out of 10, which is elevated for this asset class. With 30-day volatility of 43.0%, a beta of 0.76 and a maximum drawdown of 47.0%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
This one splits by horizon — hold in the near term, buy further out, at 7/10 long-term conviction.
The shares look undervalued, trading on 15.2 times earnings below a sector average of 29.5. The average analyst target implies 64.1% above today's level. Revenue is growing at 40.3% on a 46.6% profit margin.
Risk scores 6 out of 10, which is elevated for this asset class. With 30-day volatility of 43.0%, a beta of 0.76 and a maximum drawdown of 47.0%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
This one splits by horizon — hold in the near term, buy further out, at 7/10 long-term conviction.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 2/10
Key Factors
- Trading below the 200-day average of 102051.00
- MACD momentum is negative
- 30-day volatility of 43.0%
Medium Term
1–3 yearsPositive
Model confidence: 4/10
Key Factors
- P/E of 15.2 versus sector average of 29.5
- Trading below the 200-day average of 102051.00
- Analyst targets imply +64.1% versus the current price
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- P/E of 15.2 versus sector average of 29.5
- Analyst targets imply +64.1% versus the current price
- Profit margin of 46.6% is healthy
Key Metrics & Analysis
Financial Health
Revenue Growth40.30%
Profit Margin46.55%
P/E Ratio15.2
ROE47.91%
ROA15.98%
Debt/Equity4.78
Op. Cash Flow₩248.5B
Free Cash Flow₩112.0B
Industry P/E29.5
Technical Analysis
TrendNeutral
RSI38.3
Support₩77,200.00
Resistance₩94,800.00
MA 20₩85,840.00
MA 50₩83,278.00
MA 200₩102,051.00
MACDBearish
VolumeDecreasing
Fear & Greed Index93.14
Valuation
Fair Value₩52,318.08
Target Price₩130,333.34
Upside/Downside64.15%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta0.76
Volatility42.96%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskHigh
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.